drugset / Trial / NCT03645395
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of MT-3724 in combination with Lenalidomide in participants with relapsed or refractory B-Cell NHL.
Timeline
- Start
- 2019-04-08
- Primary completion
- 2021-03-10
- Completion
- 2021-03-10
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MT-3724 | Unknown | 10 ug/kg | Intravenous |
| Subject | MT-3724 | Unknown | 20 ug/kg | Intravenous |
| Subject | MT-3724 | Unknown | 25 ug/kg | Intravenous |
| Subject | MT-3724 | Unknown | 50 ug/kg | Intravenous |